**
In a significant development within Canada’s plasma donation landscape, Grifols, the sole operator of private plasma collection facilities in the country, has announced a temporary suspension of its donation services. This decision follows the tragic deaths of two donors and an ongoing inquiry by Health Canada into potential safety violations at its clinics. The pause in operations highlights growing concerns around donor safety and the adequacy of screening procedures in the plasma donation process.
Details of the Investigation
Health Canada’s investigation, which gained momentum after the deaths of two donors in late 2025 and early 2026, has brought to light serious questions regarding the practices employed at Grifols clinics. According to an official statement from Health Canada, the agency issued a formal notice of non-compliance regarding the company’s adherence to blood regulations, which has raised alarms among patient advocates and the general public alike.
The first of the two deaths occurred on 25 October 2025, involving 22-year-old Rodiyat Alabede, an international student in Winnipeg. Shortly after donating plasma, Alabede experienced severe distress and later died from cardiac arrest. Although Health Canada reported no direct link between her donation and her death, concerns surrounding the adequacy of her medical screening have prompted calls for further investigation. Friends and advocates have alleged that staff at the clinic may not have been properly trained to handle plasma extraction safely.
Concerns Raised by Advocates
Patient advocates, including Kat Lanteigne, who represents Alabede’s family, have underscored the need for a thorough inquiry into the circumstances surrounding her death. They claim that the practices at Grifols clinics raise significant concerns, including inadequate staff training and lapses in the execution of standard operating procedures. Allegations suggest that alarms designed to indicate distress during plasma collection were not acted upon, leading to potentially life-threatening situations for donors.
The unfolding situation has prompted a closer examination of the operational standards at Grifols clinics. Inspection reports from Health Canada have identified a range of deficiencies, including poor record-keeping and incomplete reporting. These issues, combined with the allegations surrounding Alabede’s screening, have led to an urgent demand for accountability and transparency from the company.
The Nature of Plasma Donation
Plasma, the yellowish component of blood, plays a crucial role in various bodily functions, including the transportation of blood cells and the prevention of excessive bleeding. It is also instrumental in the creation of medications for conditions such as haemophilia and certain cancers. The process of plasma donation differs markedly from standard blood donation, typically taking around 90 minutes and involving the use of an apheresis machine to separate and collect plasma while returning the remaining blood components to the donor.
The legality of paid plasma donation varies across Canada, with provinces like British Columbia and Quebec outlawing the practice. Manitoba, where the recent deaths occurred, permits such clinics, leading to a complex dialogue around the ethics and safety of compensated donations.
Grifols’ Response
In light of the ongoing investigation and increasing scrutiny, Grifols has opted to pause plasma collections at its clinics across Canada. The company characterised this decision as a proactive measure to address what it termed “unfounded attention” and to ensure collaboration with Health Canada and Canadian Blood Services. Despite the pause, Grifols maintains that the two deaths are unrelated to the plasma donation process.
Spokespersons for Grifols have expressed confidence that the suspension will not affect the overall safety and security of Canada’s blood and plasma supply. However, as investigations continue, the company faces mounting pressure to rectify operational shortcomings and restore public trust.
Why it Matters
The current crisis within Canada’s plasma donation sector raises profound questions regarding donor safety and regulatory oversight. As investigations unfold, the implications for both the healthcare system and public confidence in plasma donation practices cannot be overstated. This situation serves as a critical reminder of the need for rigorous safety standards and transparent practices within healthcare, particularly in systems reliant on voluntary contributions from the public. Ensuring the safety of donors is paramount, and any lapses could have far-reaching consequences for the healthcare landscape in Canada and beyond.
